Full Year 2023 Investor Presentation
38
Investor presentation
Full year 2023
Novo NordiskⓇ
The unmet need within diabetes care remains large with too few
patients reaching glycaemic target and treated for complications
1 in 2 adults go undiagnosed and more treated patients
should reach their HbA1c target
537m
35m
Prevalence Diagnosed
Treated
Reach target Treated for
complications
Prevalence
Of the 537 million, 40.5 million¹ people are currently treated with
Novo Nordisk diabetes products
10.4 mio treated with GLP-1
5.3 mio treated with
new-generation insulin
11.7 mio treated with
modern insulin
12.1 mio treated with
human insulins
Novo Nordisk products
Source: Diabetes prevalence and diagnosed are based on Diabetes Atlas 10th edition, 2021; Treated is based
on IQVIA patient data; real-world studies indicate between 30-55% of patients reach HbA₁ target <7%.e.g.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/
1 In addition to the above-mentioned product classes, oral anti-diabetics constitutes the remainder of people treated with Novo
Nordisk products; Estimated number for full-year 2023 (total available in Novo Nordisk Annual Report 2023)View entire presentation